

論文リスト

1. Biologic discontinuation studies: a systematic review of methods; authors' response to van der Maas et al. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. *Ann Rheum Dis.* 2013 Oct 23. doi: 10.1136/annrheumdis-2013-204617. [Epub ahead of print] No abstract available.
2. Biologic discontinuation studies: a systematic review of methods. Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH. *Ann Rheum Dis.* 2013 May 30. [Epub ahead of print]
3. Current treatments of rheumatoid arthritis: from the 'NinJa' registry. Saeki Y, Matsui T, Saisho K, Tohma S. *Expert Rev Clin Immunol.* 2012 Jul;8(5):455-65.
4. Analysis of the affected joints in rheumatoid arthritis patients in a large Japanese cohort. Kanazawa T, Nishino J, Tohma S, Tanaka S. *Mod Rheumatol.* 2012 Mar 31. [Epub ahead of print]
5. Baseline anti-citrullinated peptide antibody (ACPA) titers and serum interleukin-6 (IL-6) levels possibly predict progression of bone destruction in early stages of rheumatoid arthritis (ERA). Saeki Y, Kudo-Tanaka E, Ohshima S, Matsushita M, Tsuji SI, Maeda YI, Yoshimura M, Watanabe A, Katada Y, Harada Y, Ichikawa K, Suenaga Y, Ohta Y, Tohma S; NHO iR-net Study Group. *Rheumatol Int.* 2012 Mar 29. [Epub ahead of print]
6. HLA-A*31:01 and methotrexate-induced interstitial lung disease in Japanese rheumatoid arthritis patients: a multidrug hypersensitivity marker? Furukawa H, Oka S, Shimada K; Rheumatoid Arthritis-Interstitial Lung Disease Study Consortium, Tsuchiya N, Tohma S. *Ann Rheum Dis.* 2012 Aug 24. [Epub ahead of print] No abstract available.
7. Comparison of composite disease activity indices for rheumatoid arthritis. Matsui T, Kuga Y, Nishino J, Kaneko A, Eto Y, Tohma S. *Mod Rheumatol.* 2011 Apr;21(2):134-43. Epub 2010 Oct 23.